Noninvasive plasma-based detection of EGFR mutations using digital PCR promises a fast, sensitive and reliable approach to predicting the efficiency of EGFR-TKI. However, the low throughput and high cost of digital PCR restricts its clinical application.
We designed a digital PCR assay, which can simultaneously detect 39 mutations of exons 18–21 of the EGFR gene. To assess overall performance, retrospective FFPE tissues from 30 NSCLC patients and plasma from 33 NSCLC patients were collected and analysed.
The LoD of the EGFR mutations was as low as 0.308 copies/μL, and the linear correlation between the detected and expected values at different concentrations (0.01–10%) was low as well. Compared to ARMS-PCR in FFPE, the accuracy values of the dEGFR39 assay in plasma from 33 patients was 87.88% (29/33, 95% CI 72.67–95.18%). While monitoring the 33 patients, the EGFR mutation load as assessed by dEGFR39 was associated with the objective response to treatment. Thirteen samples from eight patients were identified by dEGFR39 to harbour the T790M mutation over time; of these patients, only nine (69%) were detected using SuperARMS.
Our results indicate that dEGFR39 assay is reliable, sensitive and cost-efficient. This method is beneficial for profiling EGFR mutations for precision therapy and prognosis after TKI treatment, especially in patients with insufficient tissue biopsy samples.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M. et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29, 2121–2127 (2011).
Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
Cheng, Y., Murakami, H., Yang, P. C., He, J., Nakagawa, K., Kang, J. H. et al. Randomized phase II trial of Gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J. Clin. Oncol. 34, 3258–3266 (2016).
Tiseo, M., Rossi, G., Capelletti, M., Sartori, G., Spiritelli, E., Marchioni, A. et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 67, 355–360 (2010).
Fenizia, F., De Luca, A., Pasquale, R., Sacco, A., Forgione, L., Lambiase, M. et al. EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncol. 11, 1611–1623 (2015).
Seki, Y., Fujiwara, Y., Kohno, T., Yoshida, K., Goto, Y., Horinouchi, H. et al. Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression. ESMO Open 3, e000292 (2018).
Vallee, A., Marcq, M., Bizieux, A., Kouri, C. E., Lacroix, H., Bennouna, J. et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 82, 373–374 (2013).
Wang, Z., Cheng, Y., An, T., Gao, H., Wang, K., Zhou, Q. et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir. Med. 6, 681–690 (2018).
Zhao, J., Zhao, J., Huang, J., Chen, Y., Jiang, J., Wu, W. et al. A novel method for detection of mutation in epidermal growth factor receptor. Lung Cancer 74, 226–232 (2011).
Li, Y., Lv, J., Wan, S., Xin, J., Xie, T., Li, T. et al. High sensitive and non-invasive ctDNAs sequencing facilitate clinical diagnosis and clinical guidance of non-small cell lung cancer patient: a time course study. Front. Oncol. 8, 491 (2018).
Li, X., Liu, Y., Shi, W., Xu, H., Hu, H., Dong, Z. et al. Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients. Clin. Chim. Acta 471, 177–184 (2017).
Jiang, X. W., Liu, W., Zhu, X. Y. & Xu, X. X. Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays. Mol. Med. Rep. 20, 593–603 (2019).
Feng, W. N., Gu, W. Q., Zhao, N., Pan, Y. M., Luo, W., Zhang, H. et al. Comparison of the superARMS and droplet digital PCR for detecting EGFR mutation in ctDNA from NSCLC patients. Transl. Oncol. 11, 542–545 (2018).
Wang, L., Guo, Q., Yu, W., Qiao, L., Zhao, M., Zhang, C. et al. Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR. Lung Cancer 114, 31–37 (2017).
Sacher, A. G., Paweletz, C., Dahlberg, S. E., Alden, R. S., O’Connell, A., Feeney, N. et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2, 1014–1022 (2016).
Zhang, X., Chang, N., Yang, G., Zhang, Y., Ye, M., Cao, J. et al. A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma. Oncotarget 8, 112014–112023 (2017).
Quan, P. L., Sauzade, M. & Brouzes, E. dPCR: a technology review. Sensors 18, 1271 (2018).
Perkins, G., Lu, H., Garlan, F. & Taly, V. Droplet-based digital PCR: application in cancer research. Adv. Clin. Chem. 79, 43–91 (2017).
Armbruster, D. A. & Pry, T. Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 29, 49–52 (2008).
Milosevic, D., Mills, J. R., Campion, M. B., Vidal-Folch, N., Voss, J. S., Halling, K. C. et al. Applying standard clinical chemistry assay validation to droplet digital PCR quantitative liquid biopsy testing. Clin. Chem. 64, 1732–1742 (2018).
Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P. et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 4, 1527–1534 (2018).
Hofman, V. & Hofman, P. Resistances to EGFR tyrosine kinase inhibitors in lung cancer-how to routinely track them in a molecular pathology laboratory? J. Thorac. Dis. 11, 65–70 (2019).
Oscorbin, I. P., Shadrina, A. S., Kozlov, V. V., Voitsitsky, V. E. & Filipenko, M. L. Absence of EGFR C797S mutation in tyrosine kinase inhibitor-naive non-small cell lung cancer tissues. Pathol. Oncol. Res. 26, 1229–1234 (2020).
Morgillo, F., Della Corte, C. M., Fasano, M. & Ciardiello, F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open 1, e000060 (2016).
Su, K. Y., Chen, H. Y., Li, K. C., Kuo, M. L., Yang, J. C., Chan, W. K. et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30, 433–440 (2012).
Decraene, C., Silveira, A. B., Bidard, F. C., Vallee, A., Michel, M., Melaabi, S. et al. Multiple hotspot mutations scanning by single droplet digital PCR. Clin. Chem. 64, 317–328 (2018).
Taly, V., Pekin, D., Benhaim, L., Kotsopoulos, S. K., Le Corre, D., Li, X. et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 59, 1722–1731 (2013).
Whale, A. S., Huggett, J. F. & Tzonev, S. Fundamentals of multiplexing with digital PCR. Biomol. Detect Quantif. 10, 15–23 (2016).
Alcaide, M., Yu, S., Bushell, K., Fornika, D., Nielsen, J. S., Nelson, B. H. et al. Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin. Chem. 62, 1238–1247 (2016).
Yu, Q., Huang, F., Zhang, M., Ji, H., Wu, S., Zhao, Y. et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients. Mol. Med. Rep. 16, 1157–1166 (2017).
Ishii, H., Azuma, K., Sakai, K., Kawahara, A., Yamada, K., Tokito, T. et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget 6, 30850–30858 (2015).
Lee, J. Y., Qing, X., Xiumin, W., Yali, B., Chi, S., Bak, S. H. et al. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget 7, 6984–6993 (2016).
Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M. & Kato, K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 99, 929–935 (2008).
Lievens, A., Jacchia, S., Kagkli, D., Savini, C. & Querci, M. Measuring digital PCR quality: performance parameters and their optimization. PLoS ONE 11, e0153317 (2016).
Gerdes, L., Iwobi, A., Busch, U. & Pecoraro, S. Optimization of digital droplet polymerase chain reaction for quantification of genetically modified organisms. Biomol. Detect Quantif. 7, 9–20 (2016).
Zhou, Q., Zhang, X. C., Chen, Z. H., Yin, X. L., Yang, J. J., Xu, C. R. et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 3316–3321 (2011).
Cui, S., Ye, L., Wang, H., Chu, T., Zhao, Y., Gu, A. et al. Use of superARMS EGFR mutation detection kit to detect EGFR in plasma cell-free DNA of patients with lung adenocarcinoma. Clin. Lung Cancer 19, 313–322 (2018).
Ethics approval and consent to participate
This study was approved (cch-BOC-1800020) by the ethics committee of Cangzhou Central Hospital, Hebei, China, and all patients provided written informed consent. This study was conducted in accordance with the Declaration of Helsinki.
Consent to publish
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
The authors declare no competing interests.
This work was funded by CIP program from Stilla technologies Co., Ltd.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Song, X., Gong, J., Zhang, X. et al. Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay. Br J Cancer 123, 1437–1444 (2020). https://doi.org/10.1038/s41416-020-1024-2